Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Womb transplant trial offers hope for women born without a uterus

NCT ID NCT05263076

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a donated uterus can help 10 women who were born without a uterus or had it removed to carry a pregnancy. Participants will receive a uterus from a living or deceased donor, then try in vitro fertilization (IVF) to become pregnant. The goal is a live birth, but recipients must take anti-rejection drugs for life, so this is a disease-control approach, not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

RECIPIENT INCLUSION CRITERIA 1. Women who are diagnosed with Absolute Uterine Factor Infertility (AUFI) and who have at least one functioning ovary. 2. Women of childbearing age (20-40 years old) who are biologically female (XX karyotype). 3. Subjects will not have active human 142 papillomavirus (HPV) or active cervical dysplasia present. 4. Subjects will have negative testing for Gonorrhea Chlamydia and Syphilis and will not have any active bacterial vaginosis or candida infection. (Subjects with previously treated STDs will be included if the infection is no longer present and has no impact. If a subject develops an STD/infection pre-operatively, she will be treated and monitored for a period of 3 months until she is no longer affected. She will then become eligible for transplant. If a subject develops an STD/infection after transplant/during pregnancy she will be treated appropriately. Prior to the embryo transfer the patient will be tested and treated if necessary. Any patient with an active STD/infection will be ineligible for any elective procedure until she is tested and treated appropriately.) 5. Subjects who are HSV-2 negative or who have a history of HSV-2 with no current symptoms. Subjects may require preventative maintenance per study doctor discretion. 6. Subjects have received counseling regarding all fertility options and alternatives to uterine transplant such as adoption or surrogate pregnancy. 7. Subjects are willing to undergo in-vitro fertilization to obtain the necessary 4 viable embryos required for eligibility for transplant if they have not already banked 4 viable embryos. 8. Subjects have been evaluated by a fertility specialist and determined to have good ovarian reserve and reproductive potential. 9. Subjects must agree that in the event of withdrawal from the study while the transplanted uterus is in place, unless she is enrolled in an equivalent uterine transplant program, she will be required to undergo a hysterectomy for her own safety. 10. Subject meets psychological recipient criteria. 11. Subject must be willing to complete questionnaires about their infant's growth and development and return them to the study team. RECIPIENT EXCLUSION CRITERIA 1. Subject with Diabetes Mellitus Type I and II by medical history or elevated hemoglobin A1c blood test. 2. Subject has known hypersensitivity to Tacrolimus, Thymoglobulin or Everolimus. 3. Subject with a diagnosis of hypertension, or any other significant medical condition that makes this procedure unsafe or is a contraindication to surgery or anesthesia. 4. Subject who has a history of solid organ or bone marrow transplant, per investigator's discretion. 5. Subject who has a history of cancer, per investigator's discretion. 6. Subject with a body mass index \>30. 7. Subject with an active infection including candida and/or bacterial vaginosis. 8. Subject who is seropositive for HIV, HBV, HCV. 9. Subject with technical obstacles as per anatomical malformations, which pose a high surgical risk in the judgment of the investigator. 10. Subject unwilling or unable to comply with study requirements. 11. Subject unable to undergo in-vitro fertilization or not cleared for transplant. 12. Subject who has smoked within the last 6 months. 13. Subject who has alcohol or drug abuse within 12 months of screening. 14. Subject with any pre-existing clinical or medical conditions that would put the subject at an increased risk. Of note, for Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome, the investigators will favor Type 1 variants as Type 2 is associated with skeletal/spinal and renal anomalies, making them higher risk candidates. DONOR INCLUSION CRITERIA 1. Women must be between 25-65 years of age. If a subject is less than 40 years old she must be certain that she does not wish to carry more children, and she will attest to this decision. 2. Subjects will not have active human 142 papillomavirus (HPV) or active cervical dysplasia present. 3. Subjects will have negative testing for Gonorrhea, Chlamydia and Syphilis and will not have any active bacterial vaginosis or candida infection. (Subjects with previously treated STDs will be included if the infection is no longer present and has no impact. If a subject develops an STD/infection pre-operatively, she will be treated and monitored for a period of 3 months until she is no longer affected. Any patient with an active STD/infection will be ineligible for any elective procedure until she is tested and treated appropriately.) 4. Subjects who are HSV-2 negative, or have a history of HSV-2 but with no current symptoms. Subjects may require preventative maintenance per study doctor discretion. 5. Subjects will have a normal uterus on sonogram and CT. 6. Subjects will have normal psychological donor criteria (if living). 7. Subjects will have had at least one prior full term live birth. DONOR EXCLUSION CRITERIA 1. Donor over the age of 65. 2. Body mass index \>30. 3. Subject with an active infection including candida and/or bacterial vaginosis. 4. Subject who is seropositive for HIV, HBV, HCV 5. Subject who has had cancer in the last five years. 6. Subject with any pre-existing clinical or medical condition that would place the subject at an increased risk or would be a contraindication to surgery or anesthesia. 7. Subject who has smoked within the last 6 months. 8. Subject who has alcohol or drug abuse within 12 months of screening. 9. Subject unwilling or unable to comply with study requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Absence of uterus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Texas Children's Hospital

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.